Combined cognitive-behavioural therapy and pharmacotherapy for adolescent depression: Does it improve outcomes compared with monotherapy?
Benedetto Vitiello, Benedetto Vitiello
Abstract
Adolescent depression can be effectively treated with selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, or with specific forms of psychotherapy, such as cognitive-behavioural therapy (CBT) and interpersonal therapy. A single course of any of these treatments, however, leaves between one-third and one-half of patients insufficiently improved and still depressed. In an effort to increase effectiveness, medication and CBT have been combined (COMB). A few controlled clinical trials have recently compared COMB with monotherapy. TADS (Treatment for Adolescents with Depression Study) randomly assigned 439 adolescents with major depressive disorder to fluoxetine, CBT, COMB or clinical management with placebo. After 12 weeks of treatment, both fluoxetine and COMB reduced depression more than CBT or placebo did, but only COMB was effective in inducing remission, achieving functional recovery and reducing suicidal ideation. After 36 weeks of treatment, there was no difference in improvement among treatments, but more suicidal events occurred in the medication only group than in the CBT only group. However, in another trial, ADAPT (Adolescent Depression and Psychotherapy Trial), involving 208 youths, no advantages of COMB over usual care with an SSRI could be detected. In a third trial, TORDIA (Treatment of Resistant Depression in Adolescence), which randomized 334 patients with an major depression unresponsive to previous SSRI treatment, COMB produced a greater response rate than medication monotherapy. These and other, smaller trials of COMB in adolescent depression are reviewed in this article. It is concluded that, while there is no univocal support for the superiority of COMB, two controlled trials indicate that COMB has a more favourable benefit/risk balance than monotherapy in adolescent depression. It remains to be determined for which patient subgroups and in which clinical settings COMB may be most advantageous.
Figures
![Figure 1. Response Rates in TADS [7,…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671638/bin/nihms-70078-f0001.jpg)
Figure 2. Remission from Depression in TADS…
Figure 2. Remission from Depression in TADS after 12 Weeks of Treatment [20]
Remission: a…
Figure 3. Level of Functioning in TADS…
Figure 3. Level of Functioning in TADS [21]
CGAS: Children's Global Assessment Scale CBT: cognitive-behavioral…
- The addition of fluoxetine to cognitive behavioural therapy for youth depression (YoDA-C): a randomised, double-blind, placebo-controlled, multicentre clinical trial.Davey CG, Chanen AM, Hetrick SE, Cotton SM, Ratheesh A, Amminger GP, Koutsogiannis J, Phelan M, Mullen E, Harrison BJ, Rice S, Parker AG, Dean OM, Weller A, Kerr M, Quinn AL, Catania L, Kazantzis N, McGorry PD, Berk M. Davey CG, et al. Lancet Psychiatry. 2019 Sep;6(9):735-744. doi: 10.1016/S2215-0366(19)30215-9. Epub 2019 Jul 29. Lancet Psychiatry. 2019. PMID: 31371212 Clinical Trial.
- The Treatment for Adolescents with Depression Study (TADS): methods and message at 12 weeks.March J, Silva S, Vitiello B; TADS Team. March J, et al. J Am Acad Child Adolesc Psychiatry. 2006 Dec;45(12):1393-403. doi: 10.1097/01.chi.0000237709.35637.c0. J Am Acad Child Adolesc Psychiatry. 2006. PMID: 17135984 Clinical Trial.
- Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.Kratochvil CJ, May DE, Silva SG, Madaan V, Puumala SE, Curry JF, Walkup J, Kepley H, Vitiello B, March JS. Kratochvil CJ, et al. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):519-27. doi: 10.1089/cap.2008.0143. J Child Adolesc Psychopharmacol. 2009. PMID: 19877976 Free PMC article.
- A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults.Skapinakis P, Caldwell D, Hollingworth W, Bryden P, Fineberg N, Salkovskis P, Welton N, Baxter H, Kessler D, Churchill R, Lewis G. Skapinakis P, et al. Health Technol Assess. 2016 Jun;20(43):1-392. doi: 10.3310/hta20430. Health Technol Assess. 2016. PMID: 27306503 Free PMC article. Review.
- Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents.Cox GR, Callahan P, Churchill R, Hunot V, Merry SN, Parker AG, Hetrick SE. Cox GR, et al. Cochrane Database Syst Rev. 2012 Nov 14;11:CD008324. doi: 10.1002/14651858.CD008324.pub2. Cochrane Database Syst Rev. 2012. PMID: 23152255 Updated. Review.
- Neural Circuits Underlying Social Fear in Rodents: An Integrative Computational Model.Alfieri V, Mattera A, Baldassarre G. Alfieri V, et al. Front Syst Neurosci. 2022 Mar 8;16:841085. doi: 10.3389/fnsys.2022.841085. eCollection 2022. Front Syst Neurosci. 2022. PMID: 35350477 Free PMC article.
- Transcranial Direct Current Stimulation as an Add-on Treatment to Cognitive-Behavior Therapy in First Episode Drug-Naïve Major Depression Patients: The ESAP Study Protocol.Carvalho S, Gonçalves ÓF, Brunoni AR, Fernandes-Gonçalves A, Fregni F, Leite J. Carvalho S, et al. Front Psychiatry. 2020 Nov 3;11:563058. doi: 10.3389/fpsyt.2020.563058. eCollection 2020. Front Psychiatry. 2020. PMID: 33240121 Free PMC article.
- The use of cognitive behavioral therapy in the treatment of resistant depression in adolescents.Hamill-Skoch S, Hicks P, Prieto-Hicks X. Hamill-Skoch S, et al. Adolesc Health Med Ther. 2012 Sep 10;3:95-104. doi: 10.2147/AHMT.S13781. eCollection 2012. Adolesc Health Med Ther. 2012. PMID: 24600290 Free PMC article. Review.
- Adolescent
- Antidepressive Agents / therapeutic use*
- Clinical Trials as Topic
- Cognitive Behavioral Therapy / methods*
- Combined Modality Therapy / methods
- Depression / drug therapy
- Depression / therapy*
- Evidence-Based Medicine / methods
- Female
- Humans
- Male
- Antidepressive Agents
![Figure 2. Remission from Depression in TADS…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671638/bin/nihms-70078-f0002.jpg)
![Figure 3. Level of Functioning in TADS…](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2671638/bin/nihms-70078-f0003.jpg)
Source: PubMed